136 related articles for article (PubMed ID: 21530824)
1. Future forms of immunotherapy and immunomodulators in allergic disease.
Nguyen TH; Stokes JR; Casale TB
Immunol Allergy Clin North Am; 2011 May; 31(2):343-65, x-xi. PubMed ID: 21530824
[TBL] [Abstract][Full Text] [Related]
2. Immunomodulators for allergic respiratory disorders.
Casale TB; Stokes JR
J Allergy Clin Immunol; 2008 Feb; 121(2):288-96; quiz 297-8. PubMed ID: 18269921
[TBL] [Abstract][Full Text] [Related]
3. Immune modulation for treatment of allergic disease.
Nguyen TH; Casale TB
Immunol Rev; 2011 Jul; 242(1):258-71. PubMed ID: 21682751
[TBL] [Abstract][Full Text] [Related]
4. Immunomodulation: the future cure for allergic diseases.
Tsitoura DC; Tassios Y
Ann N Y Acad Sci; 2006 Nov; 1088():100-15. PubMed ID: 17192559
[TBL] [Abstract][Full Text] [Related]
5. Immunotherapy in asthma.
Warrington R
Immunotherapy; 2010 Sep; 2(5):711-25. PubMed ID: 20874654
[TBL] [Abstract][Full Text] [Related]
6. Advances in upper airway diseases and allergen immunotherapy in 2007.
Saltoun C; Avila PC
J Allergy Clin Immunol; 2008 Sep; 122(3):481-7. PubMed ID: 18694591
[TBL] [Abstract][Full Text] [Related]
7. Anti-IgE antibodies for the treatment of IgE-mediated allergic diseases.
Chang TW; Wu PC; Hsu CL; Hung AF
Adv Immunol; 2007; 93():63-119. PubMed ID: 17383539
[TBL] [Abstract][Full Text] [Related]
8. Management of asthma with anti-immunoglobulin E: a review of clinical trials of omalizumab.
Nowak D
Respir Med; 2006 Nov; 100(11):1907-17. PubMed ID: 16949266
[TBL] [Abstract][Full Text] [Related]
9. TLR9-based immunotherapy for allergic disease.
Hayashi T; Raz E
Am J Med; 2006 Oct; 119(10):897.e1-6. PubMed ID: 17000223
[TBL] [Abstract][Full Text] [Related]
10. Future forms of immunotherapy.
Casale TB; Stokes JR
J Allergy Clin Immunol; 2011 Jan; 127(1):8-15; quiz 16-7. PubMed ID: 21094518
[TBL] [Abstract][Full Text] [Related]
11. [Specific immunotherapy--past--present--future].
Kägi MK
Praxis (Bern 1994); 1998 Sep; 87(40):1330-4. PubMed ID: 9816927
[TBL] [Abstract][Full Text] [Related]
12. [Development of antituberculous drugs: current status and future prospects].
Tomioka H; Namba K
Kekkaku; 2006 Dec; 81(12):753-74. PubMed ID: 17240921
[TBL] [Abstract][Full Text] [Related]
13. [The value of immunotherapy in treatment of IgE-induced allergic diseases].
Müller UR
Ther Umsch; 1994 Jan; 51(1):67-76. PubMed ID: 7511841
[TBL] [Abstract][Full Text] [Related]
14. Toll-like receptors--novel targets in allergic airway disease (probiotics, friends and relatives).
Feleszko W; Jaworska J; Hamelmann E
Eur J Pharmacol; 2006 Mar; 533(1-3):308-18. PubMed ID: 16436277
[TBL] [Abstract][Full Text] [Related]
15. [Immunomodulation therapy for allergic asthma. What is already possible, what is to come?].
Taube C; Buhl R
Dtsch Med Wochenschr; 2008 Apr; 133(14):727-32. PubMed ID: 18363195
[TBL] [Abstract][Full Text] [Related]
16. [Allergic disease treatments: classic and innovative therapeutics].
Têtu L; Didier A
Rev Prat; 2007 Jun; 57(12):1339-48. PubMed ID: 17717947
[TBL] [Abstract][Full Text] [Related]
17. Omalizumab: efficacy in allergic disease.
Spector S
Panminerva Med; 2004 Jun; 46(2):141-8. PubMed ID: 15507883
[TBL] [Abstract][Full Text] [Related]
18. Recent progress in allergen immunotherapy.
Nouri-Aria KT
Iran J Immunol; 2008 Mar; 5(1):1-24. PubMed ID: 18319521
[TBL] [Abstract][Full Text] [Related]
19. IgE-facilitated antigen presentation: role in allergy and the influence of allergen immunotherapy.
Wilcock LK; Francis JN; Durham SR
Immunol Allergy Clin North Am; 2006 May; 26(2):333-47, viii-ix. PubMed ID: 16701148
[TBL] [Abstract][Full Text] [Related]
20. The immunoglobulin E-Toll-like receptor network.
Novak N; Bieber T; Peng WM
Int Arch Allergy Immunol; 2010; 151(1):1-7. PubMed ID: 19672091
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
